Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIQD: Atazanavir vs Fosamprenavir in ARV-Naïve HIV-1 Patients
NCT00242216Phase 4Completed
- Sponsor
- UTHealth Houston
- Start
- May 2004
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in human immunodeficiency virus infection (HIV) comparing Atazanavir oral once daily with Fosamprenavir oral once daily (2 arms). Primary endpoint: Proportion of Patient With Viral Load Less Than 400 Copies/mL at 24 weeks. Started May 2004; status: completed.
02
Drugs
atazanavirfosamprenavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00242216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00242216.